focus -WSS

focus

author：fashion 2025-10-01 15:00:04 - browse：43649

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Scientific mystery highlights the blind spots in genomics databases

explore

WSS

Make 'food is medicine' a key part of White House nutrition meeting

Brain 'hot spot' may explain why African Americans feel greater pain

Meta looks to target Twitter with a rival app called Threads

Young boy dies in trial for Pfizer Duchenne gene therapy

Trial using CRISPR to edit HIV out of cells disappoints

PhRMA sues HHS over Medicare drug price negotiation

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Moonlake's readout produced a cash windfall. Risks remain

Pfizer's Covid pill remains 89% effective in final analysis, company says

Psychedelics group wrestles with new pharma identity

These geoengineering technologies could help combat the climate crisis, scientists say

Dobbs anniversary: the lost opportunity of abortion as health care

Medicare Advantage 2025 payments will dip, Biden administration says

New air purifier tech could be key to improving indoor air quality

Make 'food is medicine' a key part of White House nutrition meeting

ChatGPT in medicine: STAT answers readers' burning questions

Did the public have the right to know Arthur Ashe had AIDS?

entertainment

Researchers test human milk's ability to repair gut microbiome

Overprescribed: High cost isn't America's only drug problem

Republican states more likely to report Covid vaccine side effects

Mass General Brigham physicians react to latest merger step

Covid silver lining: Unprecedented look at human immune system

7 people shot in DC, police say

explore

leisure time

leisure time

Wikipedia